An observational study recently published in Cancer highlights a notable correlation between glucose-6-phosphate dehydrogenase (G6PD) deficiency and improved clinical outcomes among patients with ...
Retreatment with venetoclax and rituximab in CLL patients achieved 100% response rates and prolonged progression-free survival. This new study reveals venetoclax and rituximab effectively treat ...
Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma Adults 60 years or ...
Please provide your email address to receive an email when new articles are posted on . Azacitidine plus venetoclax significantly improved EFS compared with induction chemotherapy for certain patients ...
Venetoclax improved PFS but not OS in relapsed/refractory multiple myeloma, with significant benefits in t(11;14) and/or BCL2high subgroups. The overall response rate was higher with venetoclax, and ...
Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society ...
The appraisal committee considered evidence submitted by AbbVie, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full ...
The BCL2 inhibitor venetoclax has shown activity in patients with chronic lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with CLL and coexisting conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results